Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia

NCT02328755 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: peg-IFN-α
PROCEDURE: Hematopoietic Cell Transplant (HCT)
DRUG: Tacrolimus
DRUG: Methotrexate

Sponsor

University of Michigan Rogel Cancer Center